SJS Investment Consulting’s Oramed Pharmaceuticals ORMP Stock Holding History

SJS Investment Consulting’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$752	Buy	+161	New	+$728	﹤0.01%	2616

Other funds holding ORMP

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

SCM

Sage Capital Management Stockton, New Jersey $263M AUM 22.29% 1-Year Est. Return

Redwood Family Wealth Addison, Texas $113M AUM 24.54% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Glass Jacobson Investment Advisors Owings Mills, Maryland $326M AUM 13.52% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SJS Investment Consulting's ORMP Position: Q3 2026 in Review

SJS Investment Consulting opened a new position in Oramed Pharmaceuticals (ORMP) in Q3 2026: 161 shares worth $752. The stake represents ﹤0.01% of the portfolio and ranks #2616 among its holdings.

13 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

SJS Investment Consulting held 161 shares of Oramed Pharmaceuticals worth $752 as of Q3 2026.
Oramed Pharmaceuticals was a new SJS Investment Consulting position in Q3 2026.
Oramed Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2616 holding.
13 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.